Medical technology

Menopause to Become the Next Game-changer in the Global Femtech Solutions Industry by 2025

Retrieved on: 
Wednesday, June 2, 2021
Drugs, Medicine, Human development, Medical technology, Women's health, Femtech, Menopause, Medroxyprogesterone acetate

The global femtech solutions industry market is estimated to hit $1.15 billion by 2025 from $648 million in 2020, registering a compound annual growth rate (CAGR) of 12.2%.

Key Points: 
  • The global femtech solutions industry market is estimated to hit $1.15 billion by 2025 from $648 million in 2020, registering a compound annual growth rate (CAGR) of 12.2%.
  • Market expansion is being boosted by the fertility, pregnancy, and menstrual care solutions segments, along with a surge in the menopausal solutions segment, which is gaining traction with new services and solutions.
  • The study also details the femtech funding landscape and top femtech companies to watch.
  • Femtech startups should address the symptoms of menopause in innovative ways to improve life for older women.

Menopause to Become the Next Game-changer in the Global Femtech Solutions Industry by 2025

Retrieved on: 
Wednesday, June 2, 2021
Drugs, Medicine, Human development, Medical technology, Women's health, Femtech, Menopause, Medroxyprogesterone acetate

The global femtech solutions industry market is estimated to hit $1.15 billion by 2025 from $648 million in 2020, registering a compound annual growth rate (CAGR) of 12.2%.

Key Points: 
  • The global femtech solutions industry market is estimated to hit $1.15 billion by 2025 from $648 million in 2020, registering a compound annual growth rate (CAGR) of 12.2%.
  • Market expansion is being boosted by the fertility, pregnancy, and menstrual care solutions segments, along with a surge in the menopausal solutions segment, which is gaining traction with new services and solutions.
  • The study also details the femtech funding landscape and top femtech companies to watch.
  • Femtech startups should address the symptoms of menopause in innovative ways to improve life for older women.

ClearCorrect Announces Faster Manufacturing Turnaround Time for Clear Aligners

Retrieved on: 
Tuesday, June 1, 2021
Medical devices, Manufacturing, Other Manufacturing, Health, Dental, Dental equipment, Clear aligners, Straumann, Aligner, Turnaround, Manufacturing, Companies, Medical technology, Health care, ClearCorrect, Straumann, CLEARCORRECT, STRAUMANN

ClearCorrect , a Straumann Group brand and a leading manufacturer of clear aligners, announced today that it is accelerating its manufacturing turnaround time, standardizing the time from case approval to shipping to a lightning fast 10 days.

Key Points: 
  • ClearCorrect , a Straumann Group brand and a leading manufacturer of clear aligners, announced today that it is accelerating its manufacturing turnaround time, standardizing the time from case approval to shipping to a lightning fast 10 days.
  • ClearCorrect continues to regionalize its manufacturing, placing its end products closer to the user.
  • With continued global increase in demand, ClearCorrect has expanded manufacturing sites to Brazil and Germany.
  • By committing to a standard 10-day manufacturing turnaround time, ClearCorrect is raising the bar for the entire clear aligner industry and opening up new options to patients, Carsault continued.

Second Sight Medical Products Announces Results of its 2021 Annual Meeting

Retrieved on: 
Tuesday, June 1, 2021
Health, Medical devices, Other Health, Medical technology, Articles, Medicine, Emerging technologies, Medical devices, Eye, Prosthetics, Visual prosthesis, Prosthesis, COVID-19 pandemic, Second Sight, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

We are behind in our testing due to a pause in the study for the COVID-19 pandemic.

Key Points: 
  • We are behind in our testing due to a pause in the study for the COVID-19 pandemic.
  • We are finishing up our planned two-year testing with encouraging results.
  • The testing done shows that performance is good and stable over the duration of the study.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Safe Orthopaedics announces the Paris Court of Justice judgment in its favor in the infringement case against Neo Medical

Retrieved on: 
Monday, May 31, 2021
Medical specialties, Medicine, Medical device, Implant, Orthopedic surgery, Medical technology

Having discovered that the French and Swiss companies Neo Medical were importing and offering for sale on French territory products which, according to Safe Orthopaedics, reproduced the characteristics of the claims of one of its patents, Safe Orthopaedics sued the companies Neo Medical in front of the Paris Court of Justice for infringement and unfair competition.

Key Points: 
  • Having discovered that the French and Swiss companies Neo Medical were importing and offering for sale on French territory products which, according to Safe Orthopaedics, reproduced the characteristics of the claims of one of its patents, Safe Orthopaedics sued the companies Neo Medical in front of the Paris Court of Justice for infringement and unfair competition.
  • The Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spinal pathologies, and Safe Medical (formerly LCI Medical), a subcontractor of medical devices for orthopaedic surgery.
  • Safe Orthopaedics develops and manufactures kits combining sterile implants and single-use instruments, available at all times to the surgeon.
  • Safe Medical (formerly LCI Medical) produces implantable medical devices and ready-to-use instruments.

Insights on the Retinal Implants Global Market to 2027 - Featuring Abbott Vascular, Bionic Eye Technologies & Bionic Vision Australia Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 28, 2021
Optical, Health, Medical devices, Medical technology, Prosthetics, Biomedical engineering, Branches of biology, Biotechnology, Medical devices, Emerging technologies, Neuroprosthetics, Implant, Retinal implant, Retina

The "Retinal Implants - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Implants - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Implantable Miniature Telescope, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$41.8 Million by the end of the analysis period.
  • In the global Retina Implant Alpha AMS segment, USA, Canada, Japan, China and Europe will drive the 8.9% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.4 Million by the year 2027.

Vicarious Surgical CEO Adam Sachs to Present at Surgical Disruptive Technology Summit

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health informatics, Medical technology, Computer-assisted surgery, Robot-assisted surgery, Telemedicine, Health, Surgery, Vicarious, Bertin Nahum, Lindbergh operation

WALTHAM, Mass., May 27, 2021 /PRNewswire/ -- Vicarious Surgical Inc. ("Vicarious" or "Vicarious Surgical" or the "Company"), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced that Adam Sachs, Co-Founder and Chief Executive Officer of Vicarious Surgical, will participate in a panel discussion on the future of surgical robots at the Surgical Disruptive Technology Summit in Houston, Texas on June 4, 2021.

Key Points: 
  • WALTHAM, Mass., May 27, 2021 /PRNewswire/ -- Vicarious Surgical Inc. ("Vicarious" or "Vicarious Surgical" or the "Company"), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced that Adam Sachs, Co-Founder and Chief Executive Officer of Vicarious Surgical, will participate in a panel discussion on the future of surgical robots at the Surgical Disruptive Technology Summit in Houston, Texas on June 4, 2021.
  • Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs.
  • The Company's novel surgical approach uses a combination of proprietary human-like surgical robots and virtual reality to transport surgeons inside the patient to perform minimally invasive surgery.
  • The Company's technology was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), making it the first, and only, surgical robot to receive this designation from the FDA.

Dexcom Announces Upcoming Conference Presentation

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Diabetes, Health, Medical devices, Medical technology, Medicine, Health, Dexcom, Diabetes, Continuous glucose monitor, Medical monitoring, Blood glucose monitoring, Diabetes management, DXCM

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
    Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the William Blair 41st Annual Growth Stock Conference to be held virtually on Tuesday, June 1, 2021 at 12:00pm (CDT).
  • The webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference.
  • DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products.
  • By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Implicity Inc. Signs U.S. Distribution Agreement with MicroPort CRM USA

Retrieved on: 
Thursday, May 27, 2021
Medical technology, Medicine, Equipment, Microport, Microport, Medical equipment, CRM, Zimmer Biomet Robotics, Port

"We are thrilled to collaborate with MicroPort CRM.

Key Points: 
  • "We are thrilled to collaborate with MicroPort CRM.
  • Implicity is a digital MedTech created in 2016 with a global presence and a strong leadership position in Europe.
  • Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine.
  • MicroPort CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK ), with world headquarters in Clamart, near Paris, France.

RAMQ Now Offers Provincial Coverage of The Dexcom G6 Continuous Glucose Monitoring System for People Living with Type 1 Diabetes in Quebec

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Medical technology, Diabetes, Medical equipment, Dexcom, Continuous glucose monitor, Medical monitoring, Blood glucose monitoring, Diabetes management, CGM, Caregiver, Type 1 diabetes

This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes in Quebec to experience the benefits of using a CGM system for their diabetes management.

Key Points: 
  • This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes in Quebec to experience the benefits of using a CGM system for their diabetes management.
  • This announcement marks a significant accomplishment in increasing access to life changing technology used in the management of type 1 diabetes.
  • "With continuous data to help monitor her glucose levels, Dexcom G6 enables us and her caregivers to take necessary actions to manage her condition.
  • For more information about the coverage criteria for RAMQ, please visit
    Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems.